<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352105</url>
  </required_header>
  <id_info>
    <org_study_id>CCF5842</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CCF-5842</secondary_id>
    <secondary_id>ZENECA-1839/0235</secondary_id>
    <nct_id>NCT00352105</nct_id>
  </id_info>
  <brief_title>Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>A Phase I/II Trial of Concurrent Chemotherapy and ZD1839 (IRESSA) With Hyperfractionated Radiation Therapy, Followed by Maintenance ZD1839 (IRESSA) for Patients With Locally Advanced Squamous Cell Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Adelstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed
      for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving
      cisplatin, fluorouracil, and gefitinib together with radiation therapy may kill more tumor
      cells.

      PURPOSE: This phase I/II trial is studying the side effects of giving cisplatin,
      fluorouracil, and gefitinib together with hyperfractionated radiation therapy and to see how
      well they work in treating patients with locally advanced head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Explore the activity of cisplatin, fluorouracil, gefitinib, and hyperfractionated
           radiotherapy, in terms of 1-year survival and 1-year distant metastatic disease control,
           in patients with locally advanced squamous cell carcinoma of the head and neck.

      Secondary

        -  Explore the activity of this regimen, in terms of disease-specific survival and local
           control, in these patients.

        -  Assess the toxicity of this regimen in these patients.

        -  Assess the complete response rate in patients treated with this regimen.

        -  Assess the toxicity and tolerability of long-term maintenance with gefitinib in patients
           rendered disease free after this treatment regimen.

      OUTLINE: Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week,
      beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IV
      continuously over 96 hours and cisplatin IV continuously over 96 hours on days 1-4 and 22-25
      and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 3-6 months.

      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival</measure>
    <time_frame>at 1 year after start of treatment</time_frame>
    <description>To explore the activity of ZD1839 with chemotherapy and hyperfractionated radiation using 1-year survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With No Distant Metastatic Disease at 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>1-year distant metastatic disease control in patients with locally advanced squamous cell head and neck cancer. Distant disease means that cancer came back in sites outside of the head and neck.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With No Local Disease at 1 Year</measure>
    <time_frame>at 1 year after start of treatment</time_frame>
    <description>Number of Participants with No Local Disease at 1 Year. Local disease means that the cancer came back in the same site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity</measure>
    <time_frame>at 1 year after start of treatment</time_frame>
    <description>Any toxicity greater than or equal to Grade 1= mild</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Complete Response Defined as Complete Disappearance of All Clinically Detectable Tumor.</measure>
    <time_frame>3 years</time_frame>
    <description>Complete response rate per RECIST Criteria (CTC V3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Completed 2 Years of Therapy</measure>
    <time_frame>at 2 years after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Concurrent Chemotherapy and ZD1839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>20mg/m2/d IV continuous infusion x4 days</description>
    <arm_group_label>Concurrent Chemotherapy and ZD1839</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>1000mg.m2/d IV continuous x 4 days</description>
    <arm_group_label>Concurrent Chemotherapy and ZD1839</arm_group_label>
    <other_name>5FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iressa</intervention_name>
    <description>250mg/PO qd x 2 years</description>
    <arm_group_label>Concurrent Chemotherapy and ZD1839</arm_group_label>
    <other_name>ZD1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hyperfractionated radiation therapy</intervention_name>
    <description>120cGy bid</description>
    <arm_group_label>Concurrent Chemotherapy and ZD1839</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary* squamous cell carcinoma of the head and neck region,
             excluding any of the following:

               -  Nasopharynx

               -  Paranasal sinuses

               -  Salivary glands NOTE: *Primary site must be identified

          -  Locoregionally confined stage III or IV disease

               -  No evidence of nodal disease below the clavicles

               -  No distant hematogenous metastases (M0)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC &gt; 3,500/mm³

          -  Platelet count &gt; 100,000/mm³

          -  Creatinine ≤ 2.0 mg/dL

          -  Alkaline phosphatase &lt; 2 times normal

          -  AST &lt; 2 times normal

          -  Bilirubin ≤ 2.0 mg/dL

          -  Calcium normal

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Must not be a poor compliance risk for follow-up

          -  No known severe hypersensitivity to gefitinib or any excipients of this drug

          -  No evidence of clinically active interstitial lung disease

               -  Patients with chronic, stable radiographic changes who are asymptomatic are
                  eligible

          -  No unstable or uncontrolled angina, clinically apparent jaundice, or active infection

          -  No history of any other malignancy (except squamous cell or basal cell skin cancer or
             cervical carcinoma in situ) unless disease free for ≥ 5 years

          -  No other severe, uncontrolled systemic disease (e.g., unstable or uncompensated
             respiratory, cardiac, hepatic, or renal disease)

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior oncologic or other major surgery

          -  No prior definitive surgery, radiotherapy, chemotherapy, immunotherapy, or epidermal
             growth factor receptor inhibitors for head and neck cancer

          -  No investigational drugs within the past 30 days

          -  No concurrent CYP3A4 inducers, including any of the following:

               -  Phenytoin

               -  Carbamazepine

               -  Rifampin

               -  Phenobarbital

               -  Hypericum perforatum (St. John's wort)

          -  Concurrent surgery allowed provided gefitinib is not administered 2 weeks before and 2
             weeks after surgery

          -  No concurrent aminoglycoside antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Adelstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <results_first_submitted>November 17, 2011</results_first_submitted>
  <results_first_submitted_qc>January 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2012</results_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Case Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>David Adelstein</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients accrued between April 2003 and December 2007 from clinical facility</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>5-FU, Cisplatin, Radiation and Iressa</title>
          <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5-FU, Cisplatin, Radiation and Iressa</title>
          <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival</title>
        <description>To explore the activity of ZD1839 with chemotherapy and hyperfractionated radiation using 1-year survival</description>
        <time_frame>at 1 year after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-FU, Cisplatin, Radiation and Iressa</title>
            <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival</title>
          <description>To explore the activity of ZD1839 with chemotherapy and hyperfractionated radiation using 1-year survival</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With No Local Disease at 1 Year</title>
        <description>Number of Participants with No Local Disease at 1 Year. Local disease means that the cancer came back in the same site.</description>
        <time_frame>at 1 year after start of treatment</time_frame>
        <population>5 early deaths not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU, Cisplatin, Radiation and Iressa</title>
            <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Local Disease at 1 Year</title>
          <description>Number of Participants with No Local Disease at 1 Year. Local disease means that the cancer came back in the same site.</description>
          <population>5 early deaths not evaluable</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity</title>
        <description>Any toxicity greater than or equal to Grade 1= mild</description>
        <time_frame>at 1 year after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-FU, Cisplatin, Radiation and Iressa</title>
            <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity</title>
          <description>Any toxicity greater than or equal to Grade 1= mild</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Complete Response Defined as Complete Disappearance of All Clinically Detectable Tumor.</title>
        <description>Complete response rate per RECIST Criteria (CTC V3)</description>
        <time_frame>3 years</time_frame>
        <population>5 early deaths were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU, Cisplatin, Radiation and Iressa</title>
            <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Complete Response Defined as Complete Disappearance of All Clinically Detectable Tumor.</title>
          <description>Complete response rate per RECIST Criteria (CTC V3)</description>
          <population>5 early deaths were not evaluable</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Completed 2 Years of Therapy</title>
        <time_frame>at 2 years after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-FU, Cisplatin, Radiation and Iressa</title>
            <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Completed 2 Years of Therapy</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With No Distant Metastatic Disease at 1 Year</title>
        <description>1-year distant metastatic disease control in patients with locally advanced squamous cell head and neck cancer. Distant disease means that cancer came back in sites outside of the head and neck.</description>
        <time_frame>1 year</time_frame>
        <population>5 early deaths were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>5-FU, Cisplatin, Radiation and Iressa</title>
            <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Distant Metastatic Disease at 1 Year</title>
          <description>1-year distant metastatic disease control in patients with locally advanced squamous cell head and neck cancer. Distant disease means that cancer came back in sites outside of the head and neck.</description>
          <population>5 early deaths were not evaluable</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For 2 years of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5-FU, Cisplatin, Radiation and Iressa</title>
          <description>Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>&gt;= Grade 3 dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>&gt;= Grade 3 mucositis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>&gt;=Grade 3:Nausea, vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1-2 dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1-2 :Nausea, vomiting</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Grade 1-2 mucositis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Adelstein</name_or_title>
      <organization>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</organization>
      <phone>216-444-9310</phone>
      <email>adelstd@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

